Evaluation of the efficacy of clonazepam oral paste on pain of burning mouth syndrome

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120101008585N13

Enrollment

Registered

2022-02-26

Start date

2022-04-04

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burning mouth syndrome. Burn of mouth and pharynx, sequela

Interventions

Intervention 1: Intervention group: The patients will receive clonazepam oral paste three times a day for 30days. Intervention 2: Control group: The patients will receive clonazepam tab 0.5 mg and s

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: The patients with primary BMS whose disease have been confirmed by a specialist

Exclusion criteria

Exclusion criteria: The patients with primary BMS who have been under treatment for BMS during previous month The patients who have taken anxiolytics, antidepressant or any other similar medications

Design outcomes

Primary

Measure	Time frame
The amount of pain. Timepoint: Day 0,7,14,21,30. Method of measurement: Visual anloge scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Lavaee

Shiraz University of Medical Sciences

lavaeef@sums.ac.ir+98 71 3626 3193

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026